Brooks Lab.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE650L01011
NSEID: BROOKS
BSEID: 533543

INR

95.00

-1.6 (-1.66%)

BSENSE

Dec 19

BSE+NSE Vol: 39.89 k

{
  "main_header": {
    "sid": 539063,
    "name": "Brooks Lab.",
    "stock_name": "Brooks Lab.",
    "full_name": "Brooks Laboratories Ltd",
    "name_url": "stocks-analysis/brooks-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "95.00",
    "chg": -1.6,
    "chgp": "-1.66%",
    "dir": -1,
    "prev_price": "96.60",
    "mcapval": "283.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 533543,
    "symbol": "BROOKS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE650L01011",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "39.89 k",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brooks-lab-539063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Brooks Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-brooks-lab-fallingrising-3764253",
        "imagepath": "",
        "date": "2025-12-20 02:17:33",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Brooks Laboratories has been on a consistent downward trajectory, with the stock falling by 3.26% over the last week and 8.21% in the past month. This contrasts sharply with the Sensex, which recorded modest gains of 0.40% and 0.30% over the same periods respectively. The stock also hit a new 52-week low of ₹93 during intraday trading on 19-Dec, reflecting sustained selling pressure. Over the last three days alone, the stock has declined by 3.6%, signalling a lack of investor confidence in the near term.</p>\n<p>Further compounding the negative sentiment, Brooks Laboratories is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical weakness often signals bearish mome..."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.93.75",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-falls-to-52-week-low-of-rs9375-3763983",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLaborator_priceRelatedfactors_3763983.png",
        "date": "2025-12-19 12:41:37",
        "description": "Brooks Laboratories has reached a new 52-week low, with its stock price touching Rs.93.75 today. This marks a significant decline amid a broader market environment where the Sensex is trading near its yearly highs, highlighting the stock's underperformance within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.93.9 Amid Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-falls-to-52-week-low-of-rs939-amidst-continued-downtrend-3753573",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLaborator_priceRelatedfactors_3753573.png",
        "date": "2025-12-09 10:12:45",
        "description": "Brooks Laboratories has reached a new 52-week low of Rs.93.9, marking a significant decline amid a sustained downward trend over the past nine trading sessions. The stock’s performance contrasts sharply with broader market indices and sector peers, reflecting a series of financial and valuation factors influencing its current position."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.95.55",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-falls-to-52-week-low-of-rs9555-3751381",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLaborator_priceRelatedfactors_3751381.png",
        "date": "2025-12-08 11:49:25",
        "description": "Brooks Laboratories has reached a new 52-week low of Rs.95.55, marking a significant decline in its stock price amid a series of downward movements over the past week. The pharmaceutical and biotechnology company’s shares have experienced sustained pressure, reflecting ongoing concerns within the market."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.95.55",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-hits-52-week-low-amidst-continued-downtrend-3751374",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLaborator_priceRelatedfactors_3751374.png",
        "date": "2025-12-08 11:49:07",
        "description": "Brooks Laboratories has reached a new 52-week low, with its share price touching Rs.95.55 today. This marks a significant decline amid a series of consecutive trading sessions with negative returns, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Brooks Lab. Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brooks-lab-downgraded-to-strong-sell-by-marketsmojo-amid-deteriorating-fundamentals-3741047",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLab_mojoScore_3741047.png",
        "date": "2025-12-02 10:09:46",
        "description": "Brooks Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial and technical factors. The recent assessment highlights challenges in valuation and technical outlook, despite some positive financial trends, underscoring the nuanced position of the company within its sector."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.97.6",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-falls-to-52-week-low-of-rs976-3725551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrooksLaborator_priceRelatedfactors_3725551.png",
        "date": "2025-11-24 13:19:48",
        "description": "Brooks Laboratories has reached a new 52-week low of Rs.97.6, marking a significant decline in its stock price amid broader market gains. The pharmaceutical and biotechnology company’s shares have experienced a notable downturn over recent sessions, reflecting ongoing challenges in its financial performance and valuation metrics."
      },
      {
        "title": "Brooks Laboratories Q2 FY26: Sharp Profit Decline Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/brooks-laboratories-q2-fy26-sharp-profit-decline-amid-margin-pressures-3719317",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrooksLaborator_quaterlyResult_3719317.png",
        "date": "2025-11-18 15:17:04",
        "description": "Brooks Laboratories Limited, a Baddi-based contract pharmaceutical manufacturer, reported a challenging second quarter for FY2026, with consolidated net profit plunging 16.70% quarter-on-quarter to ₹7.98 crores despite maintaining year-on-year growth momentum. The micro-cap pharmaceutical company, with a market capitalisation of ₹304.00 crores, saw its stock trading at ₹103.70 on November 18, down 48.87% from its 52-week high of ₹202.80, reflecting investor concerns over deteriorating operational metrics and sustained margin pressures."
      },
      {
        "title": "How has been the historical performance of Brooks Lab.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-brooks-lab-3702972",
        "imagepath": "",
        "date": "2025-11-14 23:40:30",
        "description": "Answer:\nThe historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.\n\nBreakdown:\nBrooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar..."
      }
    ],
    "total": 246,
    "sid": "539063",
    "stock_news_url": "https://www.marketsmojo.com/news/brooks-laboratories-539063"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "Newspaper Publication dated 15th November 2025 of the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 14Th November 2025.",
      "datetime": "14-Nov-2025",
      "details": "Outcome of the Board Meeting held on Friday 14th November 2025.",
      "source": "BSE"
    },
    {
      "caption": "Results For Quarter And Half Year Ended 30Th September 2025",
      "datetime": "14-Nov-2025",
      "details": "Approved Results for quarter and half year ended 30th September 2025 at Board Meeting held on Friday 14th November 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Brooks Laboratories Ltd has announced <strong>1:16</strong> rights issue, ex-date: 28 Jul 23",
          "dt": "2023-07-28",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Why is Brooks Lab. falling/rising?

2025-12-20 02:17:33

Recent Price Movement and Market Performance

Brooks Laboratories has been on a consistent downward trajectory, with the stock falling by 3.26% over the last week and 8.21% in the past month. This contrasts sharply with the Sensex, which recorded modest gains of 0.40% and 0.30% over the same periods respectively. The stock also hit a new 52-week low of ₹93 during intraday trading on 19-Dec, reflecting sustained selling pressure. Over the last three days alone, the stock has declined by 3.6%, signalling a lack of investor confidence in the near term.

Further compounding the negative sentiment, Brooks Laboratories is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical weakness often signals bearish mome...

Brooks Laboratories Stock Falls to 52-Week Low of Rs.93.75

2025-12-19 12:41:37

Brooks Laboratories has reached a new 52-week low, with its stock price touching Rs.93.75 today. This marks a significant decline amid a broader market environment where the Sensex is trading near its yearly highs, highlighting the stock's underperformance within the Pharmaceuticals & Biotechnology sector.

Brooks Laboratories Stock Falls to 52-Week Low of Rs.93.9 Amid Prolonged Downtrend

2025-12-09 10:12:45

Brooks Laboratories has reached a new 52-week low of Rs.93.9, marking a significant decline amid a sustained downward trend over the past nine trading sessions. The stock’s performance contrasts sharply with broader market indices and sector peers, reflecting a series of financial and valuation factors influencing its current position.

Brooks Laboratories Stock Falls to 52-Week Low of Rs.95.55

2025-12-08 11:49:25

Brooks Laboratories has reached a new 52-week low of Rs.95.55, marking a significant decline in its stock price amid a series of downward movements over the past week. The pharmaceutical and biotechnology company’s shares have experienced sustained pressure, reflecting ongoing concerns within the market.

Brooks Laboratories Stock Falls to 52-Week Low of Rs.95.55

2025-12-08 11:49:07

Brooks Laboratories has reached a new 52-week low, with its share price touching Rs.95.55 today. This marks a significant decline amid a series of consecutive trading sessions with negative returns, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Brooks Lab. Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-02 10:09:46

Brooks Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial and technical factors. The recent assessment highlights challenges in valuation and technical outlook, despite some positive financial trends, underscoring the nuanced position of the company within its sector.

Brooks Laboratories Stock Falls to 52-Week Low of Rs.97.6

2025-11-24 13:19:48

Brooks Laboratories has reached a new 52-week low of Rs.97.6, marking a significant decline in its stock price amid broader market gains. The pharmaceutical and biotechnology company’s shares have experienced a notable downturn over recent sessions, reflecting ongoing challenges in its financial performance and valuation metrics.

Brooks Laboratories Q2 FY26: Sharp Profit Decline Amid Margin Pressures

2025-11-18 15:17:04

Brooks Laboratories Limited, a Baddi-based contract pharmaceutical manufacturer, reported a challenging second quarter for FY2026, with consolidated net profit plunging 16.70% quarter-on-quarter to ₹7.98 crores despite maintaining year-on-year growth momentum. The micro-cap pharmaceutical company, with a market capitalisation of ₹304.00 crores, saw its stock trading at ₹103.70 on November 18, down 48.87% from its 52-week high of ₹202.80, reflecting investor concerns over deteriorating operational metrics and sustained margin pressures.

How has been the historical performance of Brooks Lab.?

2025-11-14 23:40:30

Answer: The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years. Breakdown: Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

15-Nov-2025 | Source : BSE

Newspaper Publication dated 15th November 2025 of the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2025.